You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 21, 2024

Trandolapril; verapamil hydrochloride - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard


What are the generic drug sources for trandolapril; verapamil hydrochloride and what is the scope of freedom to operate?

Trandolapril; verapamil hydrochloride is the generic ingredient in two branded drugs marketed by Abbvie and Glenmark Pharms Ltd, and is included in two NDAs. Additional information is available in the individual branded drug profile pages.

One supplier is listed for this compound.

Summary for trandolapril; verapamil hydrochloride
Recent Clinical Trials for trandolapril; verapamil hydrochloride

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Hospital Authority, Hong KongPhase 4
Assaf-Harofeh Medical Center
Agenzia Italiana del FarmacoPhase 3

See all trandolapril; verapamil hydrochloride clinical trials

Paragraph IV (Patent) Challenges for TRANDOLAPRIL; VERAPAMIL HYDROCHLORIDE
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
TARKA Extended-release Tablets trandolapril; verapamil hydrochloride 1 mg/240 mg 020591 1 2008-02-20
TARKA Extended-release Tablets trandolapril; verapamil hydrochloride 2 mg/180 mg and 2 mg/240 mg 020591 1 2007-11-09
TARKA Extended-release Tablets trandolapril; verapamil hydrochloride 4 mg/ 240 mg 020591 1 2007-07-24

US Patents and Regulatory Information for trandolapril; verapamil hydrochloride

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Glenmark Pharms Ltd TRANDOLAPRIL AND VERAPAMIL HYDROCHLORIDE trandolapril; verapamil hydrochloride TABLET, EXTENDED RELEASE;ORAL 079135-001 May 26, 2010 RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Glenmark Pharms Ltd TRANDOLAPRIL AND VERAPAMIL HYDROCHLORIDE trandolapril; verapamil hydrochloride TABLET, EXTENDED RELEASE;ORAL 079135-003 May 5, 2010 RX No Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Abbvie TARKA trandolapril; verapamil hydrochloride TABLET, EXTENDED RELEASE;ORAL 020591-001 Oct 22, 1996 DISCN Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for trandolapril; verapamil hydrochloride

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Abbvie TARKA trandolapril; verapamil hydrochloride TABLET, EXTENDED RELEASE;ORAL 020591-003 Oct 22, 1996 ⤷  Sign Up ⤷  Sign Up
Abbvie TARKA trandolapril; verapamil hydrochloride TABLET, EXTENDED RELEASE;ORAL 020591-001 Oct 22, 1996 ⤷  Sign Up ⤷  Sign Up
Abbvie TARKA trandolapril; verapamil hydrochloride TABLET, EXTENDED RELEASE;ORAL 020591-004 Oct 22, 1996 ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.